Alumis Inc. Common Stock (ALMS) 是一家上市公司 屬於 醫療保健 板塊，經營於 生物科技 產業. 公司總部位於 South San Francisco, CA, 美国. 現任CEO為 Martin Babler.
ALMS 擁有 IPO日期為 2021-02-22, 168 名全職員工, 在 NASDAQ Global Select, 市值為 $2.98B.
Alumis Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative medicines for autoimmune and neuroinflammatory disorders. The company's lead candidate, ESK-001, is an allosteric tyrosine kinase 2 (TYK2) inhibitor in development for plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis. Additionally, Alumis is advancing A-005, a brain-penetrant TYK2 inhibitor designed to treat neuroinflammatory and neurodegenerative diseases. Founded in 2021 and formerly known as Esker Therapeutics, the company rebranded to Alumis Inc. in January 2022 and is headquartered in South San Francisco, California.
